The final part of the Congress will connect the strands of day 1 and consider what can be done. There will be a keynote on how communities can effect change followed by reports from the five Communities of Interest, concluding with a session where attendees will be asked what they want to do, or will do, as a follow-up to the Congress. Attendees will film each other outlining their commitments as part of both the larger Commons community and as part of their Community of Interest. There will then be a closing keynote including a report on the large "game changer" by Stephen Friend.
At the conclusion of the Congress attendees will understand how their own work connects to the greater movement of change in how we must approach biology and how biology relates to health care. Participants will be challenged to articulate how their work from the previous day and over the next year might lead to more sharing, better resource allocation, and faster progress. Participants will have established a set of communities ready to do active work.
Eric Schadt, PhD, is Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai. Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. He has published more than 200 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Dr. Schadt is also a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models. Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences, the next-generation sequencing technology provider. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle, and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from University of California, Davis, and his Ph.D. in bio-mathematics from University of California, Los Angeles (requiring Ph.D. candidacy in molecular biology and mathematics).